Statin therapy for the octogenarian?

Journal of Endocrinology, Metabolism and Diabetes of South Africa

Volumn 17, Issue 1, 2012, Pages 37-42

  Blom, D J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Lipoprotein metabolism; Octogenarian; Safety; Statin

Indexed keywords

AMIODARONE; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; CYTOCHROME P450 3A4; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; THYROTROPIN; UBIDECARENONE; VERAPAMIL; VERY LOW DENSITY LIPOPROTEIN;

ACUTE HEART INFARCTION; AGE; ALZHEIMER DISEASE; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COGNITION; DEMENTIA; DIABETES MELLITUS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; MILD COGNITIVE IMPAIRMENT; MORTALITY; MUSCLE DISEASE; MYALGIA; MYOPATHY; POLYPHARMACY; PRESCRIPTION; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; SYSTOLIC HEART FAILURE;

EID: 84864800816     PISSN: 16089677     EISSN: None     Source Type: Journal    
DOI: 10.1080/22201009.2012.10872272     Document Type: Review

References (42)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010;121(7):e46-e215.
2. Williams MA, Fleg JL, Ades PA, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients > or = 75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002;105(14):1735-1743.
3. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004;291(15):1864-1870.
4. Kreisberg RA, Kasim S. Cholesterol metabolism and aging. Am J Med. 1987;82(1B):54-60.
5. Ericsson S, Eriksson M, Vitols S, et al. Influence of age on the metabolism of plasma low-density lipoproteins in healthy males. J Clin Invest. 1991;87(2):591-596.
6. Poehlman ET, Toth MJ, Bunyard LB, et al. Physiological predictors of increasing total and central adiposity in aging men and women. Arch Intern Med. 1995;155(22):2443-2448.
7. Castelli WP, Wilson PW, Levy D, Anderson K. Cardiovascular risk factors in the elderly. Am J Cardiol. 1989;63(16):12H-19H.
8. Corti MC, Guralnik JM, Salive ME, et al. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med. 1997;126(10):753-760.
9. Gnavi R, Migliardi A, Demaria M, et al. Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy: a case of ageism and social inequalities. Eur J Public Health. 2007;17(5):492-496.
10. Onder G, Lattanzio F, Battaglia M, et al. The risk of adverse drug reactions in older patients: beyond drug metabolism. Curr Drug Metab Curr Drug Metab. 2011 Apr 18. [Epub ahead of print]
11. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009; 150(12):858-868.
12. Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol. 2006;97(8A):44C-51C.
13. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375(9716):735-742.
14. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360(9346):1623-1630.
15. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376(9753):1670-1681.
16. Gransbo K, Melander O, Wallentin L, et al. Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. J Am Coll Cardiol. 2010;55(13):1362-1369.
17. Nair AP, Darrow B. Lipid management in the geriatric patient. Endocrinol Metab Clin North Am. 2009;38(1):185-206.
18. Aslam F, Haque A, Lee LV, Foody J. Hyperlipidemia in older adults. Clin Geriatr Med. 2009;25(4):591-606, vii.
19. Long SB, Blaha MJ, Blumenthal RS, Michos ED. Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly. Clin Interv Aging. 2011;6:27-35.
20. Szadkowska I, Stanczyk A, Aronow WS, et al. Statin therapy in the elderly: a review. Arch Gerontol Geriatr. 2010;50(1):114-118.
21. Shanmugasundaram M, Rough SJ, Alpert JS. Dyslipidemia in the elderly: should it be treated? Clin Cardiol. 2010;33(1):4-9.
22. Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol. 2008;51(1):37-45.
23. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-1622.
24. Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischaemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007;115(6):700-707.
25. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol. 2002;39(10):1567-1573.
26. Guder G, Frantz S, Bauersachs J, et al. Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors. Circ Heart Fail. 2009;2(6):563-571.
27. Horwich TB, Hernandez AF, Dai D, et al. Cholesterol levels and inhospital mortality in patients with acute decompensated heart failure. Am Heart J 2008;156(6):1170-1176.
28. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248-2261.
29. Emberson JR, Ng LL, Armitage J, et al. N-terminal pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol. 2007;49(3):311-319.
30. Strandberg TE. Lipid-lowering drugs and heart failure: where do we go after the statin trials? Curr Opin Cardiol. 2010;25(4):385-393.
31. van Vliet P, van de Water W, de Craen AJ, Westendorp RG. The influence of age on the association between cholesterol and cognitive function. Exp Gerontol. 2009;44(1-2):112-122.
32. Okamura N, Arai H, Maruyama M, et al. Serum cholesterol and cerebrospinal fluid amyloid beta protein in Alzheimer's disease. J Am Geriatr Soc. 2001;49(12):1738-1739.
33. Kuo YM, Emmerling MR, Bisgaier CL, et al. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun. 1998;252(3):711-715.
34. Wolozin B, Wang SW, Li NC, et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007;5:20.
35. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59(2):223-227.
36. Rockwood K, Howlett S, Fisk J, et al. Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status. Neuroepidemiology 2007;29(3-4):201-207.
37. Goldstein MR, Mascitelli L, Pezzetta F, et al. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2009;72(13):1190-1191.
38. Zandi PP, Sparks DL, Khachaturian AS, et al. Do statins reduce risk of incident dementia and Alzheimer's disease? The Cache County Study. Arch Gen Psychiatry. 2005;62(2):217-224.
39. Bettermann K, Arnold AM, Williamson J, et al. Statins, risk of dementia, and cognitive function: secondary analysis of the Ginkgo Evaluation of Memory Study. J Stroke Cerebrovasc Dis. 2011 Jan 12. [Epub ahead of print].
40. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22.
41. Trompet S, Van Vliet P, De Craen AJ, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol. 2010;257(1):85-90.
42. McGuinness B, O'Hare J, Craig D, et al. Statins for the treatment of dementia. Cochrane Database Syst Rev. 2010;(8):CD007514.